Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
pdp-levETIRAcetam Levetiracetam Epilepsy Reimburse with clinical criteria and/or conditions Complete
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete
Pemazyre pemigatinib Cholangiocarcinoma Do not reimburse Complete
Pemazyre pemigatinib Cholangiocarcinoma Active
Perjeta pertuzumab Early stage breast cancer Do not reimburse Complete
Perjeta Herceptin Combo Pack Pertuzumab Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Neoadjuvant Breast Cancer Do not reimburse Complete
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Early Breast Cancer Do not reimburse Complete
Perseris risperidone Schizophrenia, adults Reimburse with clinical criteria and/or conditions Complete
Pheburane Sodium phenylbutyrate Urea cycle disorders List Complete
Picato Ingenol mebutate Actinic keratosis Do not list Complete
Picato Ingenol mebutate Actinic keratosis N/A Complete
Pifeltro doravirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Piqray alpelisib Advanced or Metastatic Breast Cancer Do not reimburse Complete
Plegridy Peginterferon beta-1a Multiple sclerosis, relapsing-remitting List with criteria/condition Complete
Pluvicto lutetium vipivotide tetraxetan Metastatic castration-resistant prostate cancer Reimburse with clinical criteria and/or conditions Complete
Polivy Polatuzumab Vedotin Diffuse large B-cell lymphoma (DLBCL) Reimburse with clinical criteria and/or conditions Complete
Polivy polatuzumab vedotin Large B-cell lymphoma Do not reimburse Complete
Polivy Resubmission polatuzumab vedotin large B-cell lymphoma (LBCL) Pending
Pomalyst Pomalidomide Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete
Pomalyst Pomalidomide Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete
Poteligeo mogamulizumab mycosis fungoides (MF), Sézary syndrome (SS) Reimburse with clinical criteria and/or conditions Complete
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete